Table 3 Fibro-scan results of the studied groups
|  | Control group (n = 142) | MAFLD group (n = 142) | MAFLD nondiabetic subgroup (n = 69) | MAFLD diabetic subgroup (n = 73) | p value | |
|---|---|---|---|---|---|---|
Fibrosis grade n (%) | F0 | 128 (90.1%) | 72 (52.8%) | 41 (59.4%) | 34 (46.6%) |  < 0.001* X2 |
F1 | 11 (7.7%) | 56 (39.4%) | 28 (40.6%) | 28 (38.4%) | ||
F2 | 3 (2.1%) | 6 (4.3%) | 0 (0.0%) | 6 (8.2%) | ||
F3 | 0 (0.0%) | 5 (3.5%) | 0 (0.0%) | 5 (6.8%) | ||
Steatosis grade n (%) | S0 | 142 (100.0%) | 0 (0.0%) | 12 (17.4%) | 2 (2.7%) |  < 0.001* X2 |
S1 | 0 (0.0%) | 25 (17.6%) | 16 (23.2%) | 9 (12.3%) | ||
S2 | 0 (0.0%) | 42 (29.6%) | 18 (26.1%) | 17 (23.3%) | ||
S3 | 0 (0.0%) | 75 (52.8%) | 23 (33.3%) | 45 (61.6%) | ||
Fibrosis score (kb) | Median [IQR] (Range) | 5.00 b,c [4.50–5.50] (3.50–8.00) | 6.00 [5.00–7.00] (3.5–12) | 5.50 a [5.00–7.00] (4.50–8.00) | 6.00 a [5.00—7.00] (3.50—12.00) |  < 0.001* Z |
Steatosis score (dm) | Median [IQR] (Range) | 110.50 b,c [99.00–123.00] (80.00–145.00) | 285.00 [260.00–310.00] (100.00–399.00) | 270.00 a,c [255.00–300.00] (100.00–366.00) | 300.00 a,b [275.00–320.00] (150.00–399.00) |  < 0.001* Z |